Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

176.45B

Market cap176.45B

Price-Earnings ratio

9.55

Price-Earnings ratio9.55

Dividend yield

3.14%

Dividend yield3.14%

Average volume

8.89M

Average volume8.89M

High today

$40.10

High today$40.10

Low today

$39.54

Low today$39.54

Open price

$39.61

Open price$39.61

Volume

6.41M

Volume6.41M

52 Week high

$64.16

52 Week high$64.16

52 Week low

$35.12

52 Week low$35.12

NVO News

Simply Wall St 6h

Novo Nordisk Could Be 62% Undervalued On GLP 1 Growth Expectations

Advertisement Recent Share Performance and Business Profile Novo Nordisk (NYSE:NVO) has been trading around US$39.14 per share, with the price moving higher o...

24/7 Wall St. 1d

Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases

Investing Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases Eli Lilly just posted a quarter that left...

TipRanks 2d

Novo Nordisk Advances Mim8 Trial in Rare Haemophilia A, Expanding Its Specialty Pipeline

Novo Nordisk (NVO) announced an update on their ongoing clinical study. The study “A Multinational, Open-label Study to Investigate Efficacy and Safety of Dene...

Analyst ratings

50%

of 6 ratings

Buy

16.7%

Hold

50%

Sell

33.3%

More NVO News

Investor's Business Daily 2d

Eli Lilly's Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Test

Technology Eli Lilly's Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Test Licensing Eli Lilly's (LLY) next-generation weight-loss drug, retatrutide, tr...

Simply Wall St 2d

Can Novo Nordisk Support A Reasonable Price On Earnings?

has been in the spotlight for its obesity treatments, yet the share price slide over the past few years raises a basic question for holders and would‑be buyers:...

The Motley Fool 3d

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

The pharmaceutical industry is evolving rapidly, leaving many investors to wonder whether established giants can sustain their momentum. Choosing between Amgen...

Benzinga 3d

Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible

Eli Lilly (NYSE:LLY) can continue running advertisements for its weight-loss medicines after a federal judge rejected Novo Nordisk A/S‘ (NYSE:NVO) request for a...

TipRanks 4d

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Novo Nordisk ( (NVO) ) just unveiled an announcement. On 26 October 2026, Novo Nordisk reported progress in a major share repurchase programme that forms part...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.